Actively Recruiting

Phase 3
Age: 6Weeks - 8Weeks
All Genders
Healthy Volunteers
NCT06413121

Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

Led by Serum Institute of India Pvt. Ltd. · Updated on 2024-09-19

1557

Participants Needed

9

Research Sites

107 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

In 2012, the World Health Assembly (WHA) endorsed the proposed Polio Endgame Strategy, which includes withdrawal of the Sabin-virus type 2 antigen-responsible for an estimated 95% of vaccine derived cases of polio by replacing the trivalent Oral Polio Vaccine (OPV) in the routine immunization schedule with a bivalent OPV that lacks the type 2 Sabin virus. Since the WHA resolution, all countries that were solely using OPV have either introduced Inactivated Polio Vaccine (IPV) into their routine immunization schedule or decided to introduce IPV but have been unable to secure supply. The global demand for IPV has therefore substantially increased in just a few years. Many initiatives are ongoing to meet the increasing demand for IPV. One potential approach is the reduction of the amount of antigen per vaccine dose. Therefore, to enhance the affordability, effectiveness and accessibility of IPV. SIIPL has manufactured hexavalent combination vaccine containing diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and a reduced dose of three IPV antigens. Based on available published data, reduction of the antigen content of each of the three poliovirus types in IPV is feasible, without substantially compromising the immunogenicity of the vaccine. Advantages of a reduction in antigen content are two-fold: increased availability of IPV and reduced cost, both of major importance for the global eradication programme.

CONDITIONS

Official Title

Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

Who Can Participate

Age: 6Weeks - 8Weeks
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female infants aged 6-8 weeks at first vaccination
  • Good health confirmed by medical history and examination
  • Signed informed consent from at least one parent
  • Born at full term (37 or more weeks gestation)
  • Weight-for-length z-score of -2 SD or higher at enrollment
  • Parent willing to follow study protocol requirements
Not Eligible

You will not qualify if you...

  • History of infections with diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, or poliomyelitis
  • Fever of 38°C (100.4°F) or higher
  • Moderate to severe acute illness
  • Antibiotic use in the past 3 days
  • Previous or planned receipt of vaccines against study diseases (except certain birth doses and trial vaccines)
  • Vaccine received in the 4 weeks before first trial vaccination (except government OPV campaign)
  • Major congenital defects or illnesses requiring medical therapy
  • Clinically significant chronic diseases affecting study evaluation
  • History of anaphylaxis or serious vaccine reactions
  • Known or suspected immune impairment or immunosuppressive therapy
  • Neurological disorders, seizures, or encephalopathy
  • Known bleeding disorders
  • Personal or maternal history of HIV, Hepatitis B, or Hepatitis C
  • Planned surgery during the study
  • Receipt or planned receipt of blood products or immunoglobulins interfering with immune assessment
  • Participation in another clinical trial within 4 weeks before enrollment or planned during this trial
  • Plans to move away from study area before study completion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 9 locations

1

International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B)

Dhaka, Bangladesh, 128

Actively Recruiting

2

Manipal Academy of Higher Education, Manipal

Mangalore, Karnataka, India, 576104

Actively Recruiting

3

JSS Medical College and Hospital

Mysore, Karnataka, India, 570004

Actively Recruiting

4

Bharati Vidyapeeth Medical College and Hospital, Pune

Pune, Maharashtra, India, 411043

Actively Recruiting

5

KEM Hospital and Research Centre, Vadu

Pune, Maharashtra, India, 412216

Actively Recruiting

6

Hamdard Institute of Medical Sciences and Research (HIMSR) with Centre for health research & Development, Society for applied studies, Hakeem Abdul Hameed Centenary Hospital (HAHCH)

New Delhi, National Capital Territory of Delhi, India, 110062

Actively Recruiting

7

Sri Ramachandra Medical Centre, Chennai

Chennai, Tamil Nadu, India, 600116

Actively Recruiting

8

Institute of Child Health, Kolkata

Kolkata, West Bengal, India, 700017

Actively Recruiting

9

Post Graduate Institute of Medical Education and Research (PGIMER)

Chandigarh, India, 160012

Actively Recruiting

Loading map...

Research Team

H

Hitt Sharma

CONTACT

S

Sameer Parekh

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here